Trust signals
> Written by the FormBlends Medical Content Team · Fact-checked against cited primary sources · Last updated May 2026
Key Takeaways
- NAD+ is a dinucleotide coenzyme, not technically a peptide; the market term "NAD peptide" refers loosely to peptide carriers, conjugates, or precursor compounds that raise intracellular NAD+ levels.
- Sirtuins (SIRT1 through SIRT7) consume one NAD+ molecule per deacetylation catalytic cycle, making NAD+ availability a genuine rate-limiting factor, not merely a correlate.
- Human pharmacokinetic trials confirm that oral NMN and NR raise blood NAD+ levels, but no human RCT has demonstrated a longevity endpoint, only biomarker shifts.
- NAD+ is hydrolysis-sensitive: lyophilized powder stored above room temperature or reconstituted and left at room temperature degrades over hours to days, not weeks.
- Importing research peptides into Canada without Health Canada authorization (prescription or SAP) risks CBSA seizure; legal domestic sources exist but require verification.
What are NAD peptides? (Direct answer)
NAD peptides are compounds, either peptide carriers conjugated to NAD+ moieties or peptides that upregulate NAD+ biosynthesis, designed to raise intracellular nicotinamide adenine dinucleotide (NAD+). NAD+ itself is a dinucleotide, not a peptide. The term is a market shorthand covering several structurally distinct compounds united by a single goal: restoring the NAD+ that declines with age.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →How do NAD peptides work at the molecular level?
NAD+ is a coenzyme present in every cell. It shuttles electrons in redox reactions (as NAD+/NADH) and serves as a consumable substrate for three enzyme families that matter most to longevity researchers:
- Sirtuins (SIRT1-SIRT7): Class III histone deacetylases. Each deacetylation reaction consumes one NAD+ molecule, releasing nicotinamide and 2'-O-acetyl-ADP-ribose as byproducts. Because nicotinamide is itself an inhibitor of sirtuins, the ratio of NAD+ to nicotinamide matters as much as absolute NAD+ concentration. SIRT1 targets include PGC-1alpha (mitochondrial biogenesis), NF-kB (inflammation), and p53 (apoptosis control).
- PARPs (PARP1/2): DNA-repair enzymes that consume large quantities of NAD+ when DNA strand breaks accumulate. Genotoxic stress can transiently deplete up to 80% of cellular NAD+ via PARP1 hyperactivation (Berger 1985, cited widely in PARP literature), which is why DNA damage and NAD+ decline are functionally linked.
- CD38: An ectoenzyme whose expression increases with age and chronic inflammation, and which hydrolyzes NAD+ to cyclic ADP-ribose. Elevated CD38 is one mechanistic explanation for the age-related NAD+ decline documented in human tissue studies.
Intracellular NAD+ levels in humans decline with age, with estimates in the range of a 40 to 60 percent reduction between young adulthood and older age in some tissues, based on human tissue biopsy data reviewed by Verdin (2015) in Science. The precise percentage varies by tissue type. This decline is directionally well-established; the exact tissue-specific numbers are still being characterized.
What this mechanism does NOT prove: Raising NAD+ in a cell culture or mouse does not automatically translate to human longevity benefit. The interventions that raised NAD+ in model organisms often involved lifelong treatment initiated at specific ages; human supplementation for months is a different intervention entirely.
What does the evidence actually show? (Evidence Ledger)
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| NAD+ declines with age in humans | Human tissue studies, cross-sectional | Consistent decline | High |
| Oral NMN raises blood NAD+ metabolites in humans | Human RCT (Yoshino et al. 2021, Cell Metabolism, n=25) | Significant increase in blood NAD+ metabolites | High |
| Oral NR raises blood NAD+ in humans | Human RCT (Trammell et al. 2016, Nature Communications) | Dose-dependent increase | High |
| NMN improves muscle insulin sensitivity in postmenopausal women | Human RCT (Yoshino et al. 2021, n=25, 10 weeks) | Improved insulin signaling gene expression in muscle | Moderate |
| NAD+ precursors extend lifespan in model organisms | Multiple animal studies (C. elegans, mice) | Generally positive, magnitude varies | Moderate (animal only) |
| NAD+ precursors extend human lifespan or reduce mortality | No human RCT with longevity endpoint exists | Unknown | Very Low |
| NAD+ reverses aging in humans | No trial; marketing claim | Not established | Very Low |
| IV or subcutaneous NAD+ is superior to oral precursors | No head-to-head human RCT | Uncertain | Very Low |
| SIRT1 activation improves metabolic markers in humans | Indirect (downstream of NAD+ studies); some supporting RCT data | Modest positive for metabolic markers | Moderate |
How do you take NAD peptides?
The answer depends on which form you are using. These are research-use protocols; this is not clinical advice.
Oral precursors (NMN, NR)
These are the best-studied forms for human use. NMN enters cells via the Slc12a8 transporter, which has been characterized in mice (Grozio et al. 2019, Nature Metabolism) and is hypothesized to exist in humans. NR converts to NMN intracellularly before entering NAD+ synthesis. Doses in human pharmacokinetic studies have ranged from 100 mg to 1000 mg per day, with blood NAD+ elevation confirmed at 250 mg to 500 mg daily in multiple trials.
Injectable NAD+ (IV or subcutaneous)
Injectable NAD+ is used in some clinical and research settings. Because NAD+ does not cross cell membranes efficiently as the intact dinucleotide (it is large, charged, and hydrophilic), IV administration raises plasma NAD+ and relies on extracellular conversion and the CD38/cyclic ADP-ribose pathway for some intracellular effects. The IV route bypasses gut degradation but introduces injection site and sterility risks. No head-to-head human RCT compares injectable NAD+ to oral precursors for any longevity endpoint.
Reconstitution (lyophilized powder)
Use bacteriostatic water. For injectable research use, standard practice is to inject solvent down the vial wall slowly to avoid foam degradation. Use immediately or store reconstituted solution at 2 to 8 degrees Celsius and discard within 24 to 48 hours (NAD+ is hydrolysis-sensitive; see chemistry section below). Do not freeze reconstituted solution.
What do most pages get wrong about NAD peptides?
1. NAD+ is not meaningfully cell-permeable as the free molecule. The intact NAD+ dinucleotide (molecular weight 663.43 g/mol, double negative charge at physiological pH) does not freely diffuse across lipid bilayers. Most intracellular NAD+ elevation from exogenous NAD+ involves extracellular enzymatic processing, not direct uptake. This is why precursors (NMN, NR) that enter cells via dedicated transporters or diffusion-aided mechanisms may actually deliver more intracellular NAD+ per dose than equivalent masses of the parent molecule. Most "NAD drip" marketing ignores this entirely.
2. PARP competition is real and underdiscussed. If a person undergoing NAD+ supplementation has high levels of genomic stress (from chemotherapy, radiation, or chronic oxidative damage), PARP1 can consume enormous amounts of NAD+, potentially negating supplementation benefits. This is not a theoretical concern; it is the mechanism behind PARP inhibitor drugs used in oncology.
3. Elevated NAD+ and cancer cell metabolism is an open question. Cancer cells have high NAD+ demand to support rapid proliferation. Several preclinical studies have examined whether NAD+ supplementation could fuel tumor growth. This does not mean supplementation causes cancer, but it is an unanswered safety question that deserves honest acknowledgment rather than silence. Regulatory guidance does not yet address this for research compounds.
4. Nicotinamide (a sirtuin inhibitor) is a metabolic byproduct. Every sirtuin reaction releases nicotinamide, which feeds back to inhibit sirtuins at elevated concentrations. The enzyme NAMPT recycles nicotinamide back into the NAD+ salvage pathway, but if this recycling is saturated, high-dose NAD+ supplementation could paradoxically cap sirtuin activity through feedback inhibition.
Why does storage and formulation matter? The chemistry behind the rules
NAD+ contains a glycosidic bond between nicotinamide and the ribose of AMP. This bond is susceptible to hydrolysis, particularly under acidic or alkaline conditions and at elevated temperatures. In solution at room temperature, free NAD+ degrades measurably within hours to days depending on pH. At pH 7.4 (physiological), NAD+ is more stable than at low pH, but temperature remains a major driver of degradation rate.
Lyophilization (freeze-drying) removes water and arrests this hydrolysis, which is why powdered NAD+ has a meaningful shelf life when kept cold and dry. Reconstitution re-introduces water and restarts the clock. This is not a recommendation for overcaution: it is chemistry. The rule "use reconstituted NAD+ promptly and refrigerate" exists because nicotinamide + ADP-ribose (the hydrolysis products) have no NAD+ activity.
Light also matters: the nicotinamide ring absorbs UV, and photodegradation contributes to potency loss. Store lyophilized and reconstituted NAD+ compounds away from direct light. Amber vials reduce this risk but do not eliminate it.
Vitamin C (ascorbic acid) is sometimes used in the same longevity stack as NAD+ precursors. While there is no direct redox conflict between ascorbic acid and NAD+ at physiological concentrations, high-dose ascorbic acid in the same IV solution can affect pH and should not be assumed safe to co-administer without formulation data.
How do NAD precursors compare to each other and to alternatives?
| Compound | Steps to NAD+ | Oral Bioavailability | Flushing Risk | Human RCT Data | Peptide Loses Here |
|---|---|---|---|---|---|
| NMN | 1 (phosphorylation) | Moderate; Slc12a8 transporter dependent | Low | Yes (Yoshino 2021) | Expensive per dose vs. niacin |
| NR (nicotinamide riboside) | 2 (to NMN then NAD+) | Moderate; well-studied in humans | Low | Yes (Trammell 2016) | Requires one extra enzymatic step vs. NMN |
| Niacin (nicotinic acid) | Several (via Preiss-Handler) | High; well-absorbed orally | High (prostaglandin D2 mediated) | Extensive (cardiovascular literature) | Tolerable only at lower doses for most; no clean longevity data |
| Niacinamide (nicotinamide) | Direct salvage | High | Negligible | Limited longevity-specific RCTs | Sirtuin inhibitor at high concentrations (feedback inhibition) |
| IV NAD+ | Extracellular conversion pathway | N/A (IV) | Low to moderate at speed | Very limited; no RCT vs. oral precursors | Invasive, expensive, no proven superiority over oral NMN/NR |
| Resveratrol (SIRT1 activator, non-NAD+) | Direct SIRT1 allosteric activation (debated) | Low (first-pass effect) | None | Mixed; some positive metabolic RCTs | Mechanism controversy; does not raise NAD+ |
Does Peptide Sciences ship to Canada? How do you get peptides in Canada?
Peptide Sciences is a US-based research peptide supplier. Their website has listed international shipping options, but they also state that customers are responsible for compliance with local laws and customs regulations. This matters enormously for Canadian buyers.
The Canadian regulatory reality
Health Canada regulates all therapeutic products under the Food and Drugs Act. Peptides intended for human use require a Drug Identification Number (DIN) or access through the Special Access Program (SAP), which is a pathway for accessing unauthorized drugs under specific medical circumstances. NAD+ and its precursors do not hold DIN status as injectable or therapeutic peptides in Canada as of early 2026.
The Canada Border Services Agency (CBSA) screens international parcels. Research peptides from the US face potential seizure if CBSA classifies them as drugs without proper authorization. In practice, small orders sometimes pass through; in practice, they sometimes do not. This is not a predictable or safe sourcing strategy.
Legal pathways for research use in Canada
- Canadian domestic research suppliers: Some operate under research-compound exemptions and ship within Canada. These suppliers provide products labeled "not for human use" for legitimate laboratory research.
- Compounding pharmacies: With a physician prescription, some Canadian compounding pharmacies can prepare NAD+ IV formulations under Health Canada's compounding provisions.
- Clinical trials: Researchers can access investigational compounds through approved clinical trial frameworks under Health Canada oversight.
How to read a COA and product label for NAD compounds
A credible Certificate of Analysis (COA) for any NAD+ compound intended for research use should contain all of the following:
| COA Element | What to Look For | Red Flag |
|---|---|---|
| HPLC purity | 98% or higher for research-grade | No purity percentage stated, or below 95% |
| Molecular weight confirmation | Must match theoretical mass (NAD+: 663.43 g/mol) | No MS data; only visual inspection noted |
| Endotoxin testing (injectable compounds) | LAL method, result below 1 EU/mg | Endotoxin test absent for injectable product |
| Mass spectrometry identity | Confirmed match to target compound | Identity stated without supporting MS spectrum |
| Lot number and date | Traceable to specific production batch | Generic or undated COA reused across products |
| Third-party testing | Independent lab, not supplier's own lab | Only internal testing documented |
What degraded NAD+ looks like: Fresh lyophilized NAD+ is typically a white to off-white powder. Yellowing or browning of the powder can indicate oxidation or thermal degradation. Reconstituted solution should be clear; cloudiness or precipitate suggests degradation or contamination. These are directional signals, not definitive tests; only HPLC confirms purity.
FAQ
What are NAD peptides?
NAD peptides are small peptide compounds, most notably NAD+ itself used in peptide contexts, or peptide precursors and cofactor-linked peptides, designed to elevate intracellular nicotinamide adenine dinucleotide (NAD+) levels. The term is sometimes used loosely to include NAD+ precursor peptides or peptides conjugated to NAD+ moieties to improve cellular uptake.
Is NAD+ itself a peptide?
Strictly speaking, NAD+ is a dinucleotide coenzyme, not a peptide. The market term "NAD peptide" typically refers to either peptides that upregulate NAD+ biosynthesis pathways or conjugate structures that combine a short peptide carrier with NAD+ precursor molecules to improve cell permeability.
How do NAD peptides work mechanically?
They work by raising intracellular NAD+ concentrations, which activates sirtuin deacetylases (SIRT1-SIRT7) and PARP1/2 DNA-repair enzymes. SIRT1 activation at elevated NAD+ levels promotes mitochondrial biogenesis via PGC-1alpha and modulates inflammation through NF-kB deacetylation.
How do you take NAD peptides?
Research protocols typically use subcutaneous injection of reconstituted lyophilized powder. Common research dosing ranges cited in literature are 100 mg to 500 mg per session. Oral bioavailability of NAD+ itself is poor; precursor forms like NMN or NR show better oral absorption in human pharmacokinetic studies.
What does NAD+ actually do to sirtuins?
Sirtuins use NAD+ as a co-substrate, consuming one NAD+ molecule per deacetylation reaction and releasing nicotinamide and the deacetylated protein plus 2'-O-acetyl-ADP-ribose. When intracellular NAD+ falls, sirtuin activity is rate-limited. Restoring NAD+ re-enables this activity rather than directly activating the enzyme.
Does Peptide Sciences ship to Canada?
Peptide Sciences lists international shipping but explicitly places customs compliance responsibility on the buyer. Canadian customs can seize research peptides. Buyers should verify current policy directly with the vendor and consult Health Canada guidance before ordering.
How do you get peptides in Canada legally?
In Canada, peptides for human use require a prescription or Special Access Program (SAP) authorization from Health Canada. Research-use peptides occupy a gray area; some Canadian-based suppliers operate under research-compound exemptions. Importing without proper authorization risks CBSA seizure and potential regulatory action.
What is the evidence quality for NAD+ and longevity?
Animal studies show consistent healthspan benefits. Human RCTs confirm that precursors safely raise blood NAD+ levels. Robust longevity endpoints in humans have not been established. Evidence quality for human longevity claims is currently low to very low.
What are the main risks or failure modes of NAD peptide protocols?
Key risks include degradation from improper storage, flushing and GI upset at higher doses, unknown long-term effects from supraphysiological NAD+ on cancer cell metabolism, and contamination risk from unregulated research-compound suppliers.
How do NAD+ precursors compare to each other?
NMN is one phosphorylation step from NAD+. NR requires conversion to NMN first. Niacin raises NAD+ effectively but causes significant flushing via prostaglandin D2 release. Direct NMN-versus-NR longevity RCTs in humans remain unpublished as of early 2026.
How do you read a COA for an NAD-related peptide compound?
A credible COA should show HPLC purity above 98%, a molecular weight match to the theoretical mass (for NAD+: 663.43 g/mol), endotoxin testing results (LAL method, below 1 EU/mg for injectable use), and a mass spectrometry identity confirmation. Absence of any one of these is a red flag.
Can NAD peptides reverse aging?
No human RCT has demonstrated reversal of aging with NAD+ precursors. Animal data show improved healthspan markers. Human trials show biomarker improvements but "reversing aging" is a marketing claim that exceeds current evidence.
Sources
- Verdin E. "NAD+ in aging, metabolism, and neurodegeneration." Science. 2015;350(6265):1208-1213.
- Yoshino M, Yoshino J, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224-1229.
- Trammell SA, Schmidt MS, et al. "Nicotinamide riboside is uniquely and orally bioavailable in healthy humans." Nature Communications. 2016;7:12948.
- Grozio A, Mills KF, et al. "Slc12a8 is a nicotinamide mononucleotide transporter." Nature Metabolism. 2019;1:47-57.
- Berger NA. "Poly(ADP-ribose) in the cellular response to DNA damage." Radiation Research. 1985;101(1):4-15.
- Chini EN, Tarragó MG, Chini CCS. "NAD and the aging process: Role in life, death and everything in between." Molecular and Cellular Endocrinology. 2017;455:62-74.
- Camacho-Pereira J, Tarragó MG, et al. "CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism." Cell Metabolism. 2016;23(6):1127-1139.
- Health Canada. Special Access Program for Drugs. Government of Canada. Accessed May 2026. canada.ca/en/health-canada/services/drugs-health-products/special-access
- Imai S, Guarente L. "NAD+ and sirtuins in aging and disease." Trends in Cell Biology. 2014;24(8):464-471.
- Cantó C, Menzies KJ, Auwerx J. "NAD+ metabolism and the control of energy homeostasis: A balancing act between mitochondria and the nucleus." Cell Metabolism. 2015;22(1):31-53.
Footer Disclaimers
Platform: FormBlends is an informational research platform. Content on this page is for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendation.
Research Compound Notice: Compounds discussed on this page are research chemicals unless otherwise specified. They are not approved by the FDA, Health Canada, or any regulatory authority for human therapeutic use outside of approved clinical frameworks. They are intended for laboratory research use only.
Results: Individual results, if any, will vary. Claims about specific outcomes have not been evaluated by regulatory agencies. Testimonials and anecdotal reports do not constitute clinical evidence.
Trademark: All product names, trademarks, and registered trademarks mentioned are the property of their respective owners. Mention does not imply endorsement or affiliation.
Evidence standard
How this page was source-checked
FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.
PubMed evidence trail
Research sources used to frame this page
For What Are NAD Peptides? How They Work, How to Take Them, and Canada Access | FormBlends, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not a claim that every study applies to every patient.
NAD+ metabolism and its roles in cellular processes during ageing
Core review for NAD+ decline, mitochondrial function, DNA repair, and aging biology.
PubMed
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Human NMN source for metabolic claims while keeping population limits clear.
PubMed
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults
Human NR source for NAD+ level and tolerability discussions.
PubMed
Peptide decision path
Move from research interest to supervised review
Direct answer
What Are NAD Peptides? How They Work, How to Take Them, and Canada Access should be evaluated through research status, legal access, source quality, safety context, and clinician oversight rather than a shortcut purchase decision.
Evidence check
Useful peptide pages should separate human data, animal research, mechanistic evidence, and marketing claims.
Safety check
Peptides can vary by legal status, compounding pathway, purity testing, patient history, and interaction risk.
Next step
If the topic still fits your goal after reading, the get-started flow should collect the clinical context needed for provider review.
Original tools and data
Use the FormBlends research stack
These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.
Editorial refresh
Practical 2026 note for What Are NAD Peptides? How They Work, How to Take Them, and Canada Access
For this peptide therapy page, the 2026 refresh focuses on safety signals, longevity, question so the article stays close to the question behind "What Are NAD Peptides? How They Work, How to Take Them, and Canada Access".
The useful details are the practical ones: what to verify, what changes risk or cost, and which details separate What Are NAD Peptides? How They Work, How to Take Them, and Canada Access from nearby GLP-1, peptide, hormone, or provider-comparison searches.
Readers can use the added context to bring sharper questions to a licensed provider before making a treatment, cost, or care decision.
Custom 2026 image for What Are NAD Peptides? How They Work, How to Take Them, and Canada Access, peptide therapy, and better treatment decision-making.
Download the Peptide Quick Reference Card
A printable 2-page reference covering popular peptides, dosing ranges, stacking protocols, and storage.
Free download. We'll also send helpful GLP-1 guides to your inbox. Unsubscribe anytime.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.
Written by the FormBlends Medical Content Team
Medical content team. This article was researched against primary regulatory, trial, prescribing, and manufacturer sources where available. Reviewed by Verdin (2015) in Science. The precise percentage varies by tissue type. This decline is directionally well-established; the exact tissue-specific numbers are still being characterized. for medical accuracy, sourcing, and patient-safety framing.